iBio, Inc. (NYSEAMERICAN:IBIO) Sees Large Growth in Short Interest

iBio, Inc. (NYSEAMERICAN:IBIO) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 255,800 shares, a growth of 26.1% from the November 30th total of 202,800 shares. Currently, 2.8% of the shares of the stock are short sold. Based on an average daily volume of 143,900 shares, the days-to-cover ratio is currently 1.8 days.

iBio Price Performance

Shares of IBIO stock opened at $2.38 on Tuesday. iBio has a 52 week low of $1.02 and a 52 week high of $4.98. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.